Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL
Publication
, Conference
Clegg, LE; Penland, RC; Bachina, S; Boulton, DW; Thuresson, M; Heerspink, HJL; Gustavson, S; Sjostrom, CD; Ruggles, J; Hernandez, AF; Buse, JB ...
Published in: DIABETOLOGIA
September 1, 2019
Duke Scholars
Published In
DIABETOLOGIA
EISSN
1432-0428
ISSN
0012-186X
Publication Date
September 1, 2019
Volume
62
Start / End Page
S4 / S5
Location
Barcelona, SPAIN
Publisher
SPRINGER
Conference Name
55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)
Related Subject Headings
- Endocrinology & Metabolism
- 4206 Public health
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., … Holman, R. R. (2019). Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL. In DIABETOLOGIA (Vol. 62, pp. S4–S5). Barcelona, SPAIN: SPRINGER.
Clegg, L. E., R. C. Penland, S. Bachina, D. W. Boulton, M. Thuresson, H. J. L. Heerspink, S. Gustavson, et al. “Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL.” In DIABETOLOGIA, 62:S4–5. SPRINGER, 2019.
Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, et al. Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL. In: DIABETOLOGIA. SPRINGER; 2019. p. S4–5.
Clegg, L. E., et al. “Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL.” DIABETOLOGIA, vol. 62, SPRINGER, 2019, pp. S4–5.
Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjostrom CD, Ruggles J, Hernandez AF, Buse JB, Mentz RJ, Holman RR. Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL. DIABETOLOGIA. SPRINGER; 2019. p. S4–S5.
Published In
DIABETOLOGIA
EISSN
1432-0428
ISSN
0012-186X
Publication Date
September 1, 2019
Volume
62
Start / End Page
S4 / S5
Location
Barcelona, SPAIN
Publisher
SPRINGER
Conference Name
55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)
Related Subject Headings
- Endocrinology & Metabolism
- 4206 Public health
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences